-
2024-510580-28-00
5
2019-06-05
Middle or low locally advanced resectable rectal carcinoma
-
2024-515690-10-00
9
2019-05-10
Follicular B-cell non-Hodgkin's lymphoma
-
2023-508302-24-00
4
2019-05-07
Locally Advanced/Metastatic Urothelial Cancer
-
2024-512173-27-00
5
2019-03-21
Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment wi
-
2024-512002-26-00
4
2019-02-19
Muscle-invasive bladder cancer
-
2024-512629-97-00
4
2019-01-23
Patients with locally advanced or metastatic low grade endometrial str
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2024-514780-26-00
4
2018-10-23
Patients ≤50 years old with high-risk osteosarcoma (defined as metasta
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2023-503629-20-00
9
2018-06-27
Metastatic breast cancer, including triple negative breast cancer (TNB
-
2024-513627-16-01
7
2018-03-28
Colorectal cancer metastatic
-
2024-514238-19-00
4
2018-03-28
Subjects with advanced solid tumour
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2024-516810-39-00
4
2018-02-13
Adjuvant therapy after salvage surgery of high risk recurrent head and
-
2023-509318-13-00
6
2018-01-15
Multiple indications
-
2023-506987-15-00
9
2016-11-17
Metastatic Castration-Resistant Prostate Cancer
-
2024-515678-29-00
4
2016-11-15
Patients with metastatic tumours (colorectal, non-small cell lung, ren
-
2024-514791-40-00
9
2016-08-03
pediatric cancer
-
2024-516103-16-00
4
2015-12-04
Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2022-501257-36-00
9
2015-03-19
Treatment of advanced melanoma, or advanced, relapsed or
refractory PD
-
2023-506027-29-00
5
2014-10-01
Children, adolescents and adults with newly diagnosed diffuse intrinsi
-
2024-511344-11-00
1
2014-07-18
AG-120 is being investigated for the treatment of patients with advanc
-
2024-517390-24-00
5
2011-04-26
Ovarian epithelial cancer : intraperitoneal resectable relapse